IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinoma.
Cui C, Li J, Yang Y, Si L, Chi Z, Mao L, Wang X, Tang B, Yan X, Li S, Zhou L, Wei X, Shen Y, Guo Q, Zheng S, Guo J, Lian B.
Cui C, et al. Among authors: shen y.
Innovation (Camb). 2024 May 10;5(4):100638. doi: 10.1016/j.xinn.2024.100638. eCollection 2024 Jul 1.
Innovation (Camb). 2024.
PMID: 38881798
Free PMC article.